Article Cell Based Assays Disease 
Broad Institute
JUNE 30, 2023
Common genetic variants associated with cardiometabolic disease can produce phenotype changes of such small effect that they can be difficult to characterize. Fat cells stained yellow to show the actin cytoskeleton, plasma membrane, and Golgi apparatus. Credit: Phil Kubitz, Claussnitzer lab Fat cells stained blue to show nuclei. “I
Drug Target Review
MAY 3, 2024
This is especially true in domains such as protein structure, predictive binding kinetics, and even in larger systemic investigations like cell migration models or disease progression. At Beckman Coulter Life Sciences , he supports the applications development team in NGS, cell-based assays, and proteomics workflows.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Molecular Design
DECEMBER 19, 2023
I’ll be taking a look at H2023 (Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes) in this post and this article has also been discussed In The Pipeline. Subscripting doesn't work well in blogger and so I'll use K.i As measurement of k.inact/K.i
Drug Target Review
OCTOBER 24, 2024
Janette Thomas leads a small biotech company (Five Alarm Bio) 1 on a mission to develop drugs targeting the chronic diseases associated with ageing. Her company’s focus includes dementia, muscle wasting, and chronic wounds – diseases that disproportionately affect the elderly. Reference 1 Five Alarm Bio. cited 2024 Oct 17].
Agency IQ
APRIL 12, 2024
Cell-based assays , while more complex to develop and use, offer another option for characterizing product activity at a slightly higher level, allowing sponsors to measure the further downstream effects of products (e.g., morphological cell changes or alterations in protein production or expression).
Expert insights. Personalized for you.
105 
Let's personalize your content